Aligos officer granted 9,450 stock options

Aligos Therapeutics, Inc. principal accounting officer Nikhil Aneja received a grant of stock options covering 9,450 shares of common stock at an exercise price of $7.0300 per share.

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. principal accounting officer Nikhil Aneja received a grant of stock options covering 9,450 shares of common stock at an exercise price of $7.0300 per share. These options were awarded as compensation and do not represent an open-market purchase or sale.

According to the vesting terms, 1/48th of the total options vest in equal monthly installments starting on March 9, 2026, so all 9,450 options are scheduled to be fully vested and exercisable by the fourth anniversary of that vesting commencement date, contingent on continued service.

Insider Trade Summary

Grant/Award: 9,450 shares

Grant/Award 1 txn

Insider Aneja Nikhil

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,450	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 9,450 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos Therapeutics (ALGS) disclose about Nikhil Aneja’s Form 4 transaction?

Aligos Therapeutics reported that principal accounting officer Nikhil Aneja received a grant of stock options for 9,450 shares at an exercise price of $7.0300. This is a compensation-related award, not an open-market trade, and reflects additional potential equity exposure.

How many stock options did Nikhil Aneja receive in the latest ALGS Form 4?

Nikhil Aneja was granted stock options covering 9,450 shares of Aligos Therapeutics common stock. The options are a derivative security giving him the right to buy shares at a fixed exercise price if they vest and he chooses to exercise them.

What is the exercise price of the stock options granted to Nikhil Aneja at Aligos Therapeutics (ALGS)?

The granted options have an exercise price of $7.0300 per share. This means Aneja can purchase Aligos Therapeutics common stock at that price upon vesting and exercise, regardless of the market price at that time, subject to the plan terms.

How do the stock options granted to Nikhil Aneja at ALGS vest over time?

The options vest in 48 equal monthly installments starting on March 9, 2026. Each month, 1/48th of the 9,450 options becomes exercisable, so the entire grant is scheduled to be fully vested on the fourth anniversary of that vesting commencement date.

Is Nikhil Aneja’s Form 4 transaction for ALGS a stock purchase or a grant?

The Form 4 shows a grant of stock options, not an open-market stock purchase. The transaction is coded as a grant or award acquisition, reflecting compensation rather than a discretionary buy or sell in the public market.

How many Aligos Therapeutics (ALGS) options does Nikhil Aneja hold after this Form 4 transaction?

After this transaction, Aneja holds 9,450 stock options as reported in the filing. These options are subject to the specified vesting schedule and give him potential future rights to acquire common shares at the fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aneja Nikhil

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

ONE CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.03	03/09/2026		A		9,450		(1)	03/09/2036	Common Stock	9,450	$0	9,450	D

Explanation of Responses:

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Nikhil Aneja	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.